Senti Biosciences Holdings, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
SNTI$0.16-0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| June 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $6,463 | $16,420 |
| Accounts receivable | — | 323 |
| GeneFab receivable - related party | 557 | 1,272 |
| GeneFab prepaid expenses - related party | 4,932 | 3,604 |
| Prepaid expenses and other current assets | 1,055 | 1,655 |
| Total current assets | 13,007 | 23,274 |
| Restricted cash | 1,426 | 3,528 |
| Property and equipment, net | 11,433 | 12,886 |
| Operating lease right-of-use assets | 7,239 | 11,516 |
| Other non-current assets | — | 19 |
| TOTAL ASSETS | $33,105 | $51,223 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $2,248 | $2,943 |
| Accrued expenses and other current liabilities | 4,082 | 5,354 |
| Convertible notes - related party | 3,993 | — |
| Operating lease liabilities, current | 3,492 | 5,330 |
| GeneFab sublease deferred income - related party | 1,939 | 304 |
| Deferred revenue - related party | 11 | 43 |
| Total current liabilities | 15,765 | 13,974 |
| Operating lease liabilities, non-current | 12,741 | 23,561 |
| Other non-current liabilities | 8,000 | 8,099 |
| TOTAL LIABILITIES | 36,506 | 45,634 |
| Commitments and contingencies (Note 14) | ||
| STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Common stock, $0.0001 par value; 500,000,000 shares authorized as of both June 30, 2026 and December 31, 2025; 31,144,754 and 30,879,355 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 3 | 3 |
| Additional paid-in capital | 372,139 | 364,158 |
| Accumulated deficit | (375,543) | (358,572) |
| TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) | (3,401) | 5,589 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | $33,105 | $51,223 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.